RxDoctor Payments Data

Joseph Henske, MD

Endocrinology, Diabetes & Metabolism · Little Rock, ARNPI 1366635807

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $16,984 of the $22,787 with a category attached, or 74.5%. Novo Nordisk accounts for 66.7% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $15,233 and has fallen 97.0% since, to $462 in 2025.

$22,787in general payments, 2019–2025

Across 92 payments — averaging $247.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$15K
  • Dexcom, Inc.$6K
  • AbbVie$462
  • AstraZeneca$143
  • Johnson & Johnson$135
  • Sanofi-aventis U.S. LLC$97
  • plus $669 from 14 others

What the payments were for

  • Consulting fees$4,41719%
  • Speaking & faculty fees$16,98475%
  • Travel & lodging$460%
  • Food & beverage$1,3406%

General payments by program year

19
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,787 in reported general payments places this provider in the 65th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.

See all endocrinology, diabetes & metabolism providers in Arkansas

Medicare billing

Part B allowed, 2024
$45,974
Medicare patients
191
Services billed
705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide328$402,542
MounjaroTirzepatide258$322,211
JardianceEmpagliflozin150$144,304
TrulicityDulaglutide95$117,829
Tresiba Flextouch U-200Insulin Degludec50$65,833
Humulin R U-500 KwikpenInsulin Regular, Human22$41,443
Tresiba Flextouch U-100Insulin Degludec60$36,993
Humalog Kwikpen U-100Insulin Lispro68$32,499
Fiasp FlextouchInsulin Aspart (Niacinamide)38$31,806
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog39$31,667
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog51$30,039
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog63$28,832
Novolog FlexpenInsulin Aspart108$27,280
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/737$26,616
Lantus SolostarInsulin Glargine,hum.Rec.Anlog140$21,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$23$447,723427 claims
Novo NordiskOzempic, Fiasp, Novolog$15,204$426,563383 claims
Boehringer IngelheimJardiance, Synjardy$63$150,820161 claims
AstraZenecaFarxiga$143$19,17027 claims
Sanofi-aventis U.S. LLCLantus$97$2,63522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.

Other endocrinology, diabetes & metabolism in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →